Physician profile
Lora Baker
NPI 1235114331
$1,894.72
in general payments reported to CMS, 2019-2025
15 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.38 · 2020: $28.06 · 2021: $266 · 2022: $195 · 2023: $260 · 2024: $397 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $627.07 | 2023-2025 | Grafix Pl, Stravix Pl, Oasis Micro |
| Stryker Corporation | $584.56 | 2021-2025 | Augment Injectable, Phalinx, Ortholoc 2 Lapifuse |
| Organogenesis INC. | $244.33 | 2021-2025 | Puraply, Novachor |
| Averitas Pharma INC. | $84.40 | 2023-2025 | Qutenza |
| Nevro Corp. | $69.80 | 2024 | Senza |
| Convatec INC. | $56.71 | 2024 | |
| Grt US Holding, INC. | $53.05 | 2022 | |
| Kci USA, INC. | $29.47 | 2019 | |
| Djo, LLC | $29.08 | 2019 | |
| Zyla Life Sciences, INC. | $28.06 | 2020 | |
| Kerecis Limited | $21.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $20.22 | 2024 | Nuzyra |
| Novus Surgical Consultants | $17.99 | 2025 | |
| Globus Medical, INC. | $17.32 | 2025 | Senza |
| Integra Lifesciences Corporation | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.